Keros Therapeutics (KROS) Equity Ratio (2019 - 2025)
Historic Equity Ratio for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to 0.95.
- Keros Therapeutics' Equity Ratio rose 297.71% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year increase of 297.71%. This contributed to the annual value of 0.93 for FY2024, which is 336.43% up from last year.
- As of Q3 2025, Keros Therapeutics' Equity Ratio stood at 0.95, which was up 297.71% from 0.93 recorded in Q2 2025.
- Keros Therapeutics' 5-year Equity Ratio high stood at 0.97 for Q2 2021, and its period low was 0.9 during Q4 2023.
- Over the past 5 years, Keros Therapeutics' median Equity Ratio value was 0.93 (recorded in 2022), while the average stood at 0.93.
- Its Equity Ratio has fluctuated over the past 5 years, first soared by 33481.7% in 2021, then plummeted by 507.86% in 2022.
- Over the past 5 years, Keros Therapeutics' Equity Ratio (Quarter) stood at 0.95 in 2021, then dropped by 5.08% to 0.9 in 2022, then fell by 0.72% to 0.9 in 2023, then rose by 3.36% to 0.93 in 2024, then rose by 2.07% to 0.95 in 2025.
- Its Equity Ratio was 0.95 in Q3 2025, compared to 0.93 in Q2 2025 and 0.93 in Q1 2025.